Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study

The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to p...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 670900
Main Authors Sun, Yiting, Jiang, Liqing, Wen, Ti, Guo, Xiaoyu, Shao, Xinye, Qu, Hui, Chen, Xi, Song, Yujia, Wang, Fang, Qu, Xiujuan, Li, Zhi
Format Journal Article
LanguageEnglish
Published Frontiers Media S.A 17.08.2021
Subjects
bibliometrics
immune checkpoint blockade
meta-analysis
PD1/PDL1
Pharmacology
randomized clinical trials
Online AccessGet full text

Cover

Abstract The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to provide a comprehensive bibliometric analysis of the literature on anti-PD1/PDL1 from three perspectives including molecular mechanisms, randomized clinical trials (RCT), and meta-analysis, thus producing a knowledge map reflecting the status of the research, its historical evolution, and developmental trends in related research from 2000 to 2020. We included 11,971, 191, and 335 documents from the Web of Science Core Collection database, respectively, and adopted various bibliometric methods and techniques thereto. The study revealed the major research themes and emergent hotspots based on literature and citation data and outlined the top contributors in terms of journals and countries. The co-occurrence overlay of keywords and terms pertaining to the PD1/PDL1 molecule reflected the progress from the discovery of the PD1/PDL1 molecule to the clinical application of anti-PD1/PDL1. Immune-related adverse events (irAEs) formed a unique cluster in the term co-occurrence analysis of meta-analysis. The historical direct citation network of RCT indicated the development and transformation of cancers and therapy strategies. irAEs and the strategies of combination therapy might become a future focus of research in this cognate area. In summary, the bibliometric study provides a general overview of the landscape on anti-PD1/PDL1 research, allowing researchers to identify the potential opportunities and challenges therein.
AbstractList The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer immunotherapy. The related literature shows the explosive growth trends due to the promising outcomes of tumor regression. The present study aimed to provide a comprehensive bibliometric analysis of the literature on anti-PD1/PDL1 from three perspectives including molecular mechanisms, randomized clinical trials (RCT), and meta-analysis, thus producing a knowledge map reflecting the status of the research, its historical evolution, and developmental trends in related research from 2000 to 2020. We included 11,971, 191, and 335 documents from the Web of Science Core Collection database, respectively, and adopted various bibliometric methods and techniques thereto. The study revealed the major research themes and emergent hotspots based on literature and citation data and outlined the top contributors in terms of journals and countries. The co-occurrence overlay of keywords and terms pertaining to the PD1/PDL1 molecule reflected the progress from the discovery of the PD1/PDL1 molecule to the clinical application of anti-PD1/PDL1. Immune-related adverse events (irAEs) formed a unique cluster in the term co-occurrence analysis of meta-analysis. The historical direct citation network of RCT indicated the development and transformation of cancers and therapy strategies. irAEs and the strategies of combination therapy might become a future focus of research in this cognate area. In summary, the bibliometric study provides a general overview of the landscape on anti-PD1/PDL1 research, allowing researchers to identify the potential opportunities and challenges therein.
Author Shao, Xinye
Chen, Xi
Wen, Ti
Guo, Xiaoyu
Song, Yujia
Sun, Yiting
Li, Zhi
Wang, Fang
Qu, Xiujuan
Jiang, Liqing
Qu, Hui
AuthorAffiliation 1 Department of Medical Oncology, The First Hospital of China Medical University, Shenyang , China
3 Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang , China
4 Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang , China
2 Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang , China
AuthorAffiliation_xml – name: 4 Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University, Shenyang , China
– name: 3 Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University, Shenyang , China
– name: 1 Department of Medical Oncology, The First Hospital of China Medical University, Shenyang , China
– name: 2 Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang , China
Author_xml – sequence: 1
  givenname: Yiting
  surname: Sun
  fullname: Sun, Yiting
– sequence: 2
  givenname: Liqing
  surname: Jiang
  fullname: Jiang, Liqing
– sequence: 3
  givenname: Ti
  surname: Wen
  fullname: Wen, Ti
– sequence: 4
  givenname: Xiaoyu
  surname: Guo
  fullname: Guo, Xiaoyu
– sequence: 5
  givenname: Xinye
  surname: Shao
  fullname: Shao, Xinye
– sequence: 6
  givenname: Hui
  surname: Qu
  fullname: Qu, Hui
– sequence: 7
  givenname: Xi
  surname: Chen
  fullname: Chen, Xi
– sequence: 8
  givenname: Yujia
  surname: Song
  fullname: Song, Yujia
– sequence: 9
  givenname: Fang
  surname: Wang
  fullname: Wang, Fang
– sequence: 10
  givenname: Xiujuan
  surname: Qu
  fullname: Qu, Xiujuan
– sequence: 11
  givenname: Zhi
  surname: Li
  fullname: Li, Zhi
BookMark eNpV0stu1DAUBuAIFdELfQB2XrLJ1LckNguk6RTKSCNRQVlbvpw0bhM7OEml2fHoZCYVot7YPj76zsL_eXYSYoAs-0DwijEhr-q-0WlFMSWrssIS4zfZGSlLlktB6Ml_59Pschge8byYlKzk77JTxrmQpSRn2Z_7BMENyAc0NoB-wAA62QZtwxjRtuumAGjTgH3qow8jum6jfdIOkNmjdRh9fndDru5uduR4M9F5OFobHSykBYgznHS__4TW6Nqb1scOxuQt-jlObv8-e1vrdoDLl_0i-_X1y_3mW777frvdrHe55ZyOuTaiFrSgXFQOypoYZwnYuVrYujK1kRycKGrATtBSV7UxVFgrLRfOCMscu8i2i-uiflR98p1OexW1V8dCTA9Kp9HbFlStaeHwTLDC8kLiGXLcUVvgqgQmD9bnxeon04GzEMak21fo65fgG_UQn5XgRBCCZ-DjC5Di7wmGUXV-sNC2OkCcBkWLChPC5w-bW8nSalMchgT1vzEEq0MQ1DEI6hAEtQSB_QVtsKpT
CitedBy_id crossref_primary_10_1007_s13353_024_00841_8
crossref_primary_10_3389_fimmu_2022_967076
crossref_primary_10_3389_fphar_2022_927219
crossref_primary_10_3389_fimmu_2022_862084
crossref_primary_10_3389_fonc_2022_999203
crossref_primary_10_3389_fddsv_2022_1032587
crossref_primary_10_1016_j_gendis_2022_07_024
Cites_doi 10.1056/NEJMoa1816047
10.1016/j.jbusres.2018.12.002
10.1038/s41591-018-0197-1
10.1002/j.1460-2075.1992.tb05481.x
10.4049/jimmunol.1202777
10.2217/fon-2018-0581
10.1084/jem.193.7.839
10.1186/s40364-020-00212-5
10.1200/jco.2017.77.6385
10.1084/jem.192.7.1027
10.1038/nm730
10.1038/s41571-020-00449-x
10.1158/0008-5472.can-03-3259
10.3389/fimmu.2020.598877
10.1136/jitc-2019-000492corr1
10.1002/asi.20317
10.1016/j.jtho.2018.11.028
10.1093/jnci/djab035
10.3389/fphar.2017.00561
10.1097/md.0000000000010276
10.1038/s41590-019-0512-0
10.1053/j.seminoncol.2018.08.007
10.1155/2018/5068701
10.1158/1078-0432.ccr-15-3101
10.1038/70932
10.1080/2162402x.2019.1682383
10.3389/fphar.2018.01050
10.1016/j.joi.2017.08.007
10.1084/jem.20180684
10.1186/s13045-019-0738-1
10.3389/fphar.2020.00441
10.1016/j.immuni.2016.05.001
10.1016/bs.acr.2019.03.002
10.1001/jamaoncol.2020.0726
10.1038/s41423-019-0341-y
10.2147/cmar.S270099
10.1186/s13613-020-00761-w
10.1016/j.ejca.2020.03.017
10.1016/j.intimp.2019.03.045
10.1371/journal.ppat.1005374
10.2196/18228
10.1016/j.annonc.2021.02.006
10.1038/s41467-020-15679-x
10.1038/s41571-019-0218-0
10.1038/85330
10.1016/j.jtho.2018.03.035
10.1108/03090561011008583
10.1001/jamaoncol.2019.2785
10.1038/s41419-020-03173-7
10.1080/14616688.2019.1666913
10.1016/j.lungcan.2019.07.004
10.1186/s12943-018-0864-3
10.3389/fcell.2020.00672
10.1016/j.joi.2016.11.007
10.1001/jamaoncol.2018.5904
10.1038/nrclinonc.2016.25
10.1038/s41591-021-01323-8
10.1016/j.critrevonc.2020.103161
10.1177/1176935119852620
10.1073/pnas.1918937117
10.1016/j.jtho.2018.02.022
10.1158/1078-0432.ccr-20-1523
10.3389/fimmu.2020.01187
10.21037/atm.2017.06.11
10.1016/s1470-2045(18)30261-4
10.1108/imr-10-2014-0341
10.1200/jco.19.03296
10.3390/antiox9050439
10.1007/s11192-010-0259-8
10.1007/s00262-019-02453-2
10.1007/s11192-009-0146-3
10.1016/j.intimp.2020.106876
10.1038/s41591-020-01211-7
10.3390/cancers12092418
10.1108/ijchm-10-2018-0828
10.1155/2020/4708394
10.1038/s41591-018-0198-0
10.1634/theoncologist.2019-0637
10.1080/21645515.2016.1199310
10.1038/nature10673
10.3389/fimmu.2021.669539
10.1016/j.jtho.2020.03.002
10.1158/0008-5472.1089.65.3
10.1038/nri.2016.90
10.1172/jci132712
10.1038/nrc3239
10.1080/2162402x.2019.1586409
10.1158/2159-8290.Cd-19-1384
10.1016/j.canlet.2017.11.014
10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9
10.1093/jnci/djz094
10.1158/2159-8290.Cd-19-0644
10.1186/s40425-016-0196-z
10.1186/s13045-021-01105-2
10.1016/j.cell.2020.06.001
ContentType Journal Article
Copyright Copyright © 2021 Sun, Jiang, Wen, Guo, Shao, Qu, Chen, Song, Wang, Qu and Li. 2021 Sun, Jiang, Wen, Guo, Shao, Qu, Chen, Song, Wang, Qu and Li
Copyright_xml – notice: Copyright © 2021 Sun, Jiang, Wen, Guo, Shao, Qu, Chen, Song, Wang, Qu and Li. 2021 Sun, Jiang, Wen, Guo, Shao, Qu, Chen, Song, Wang, Qu and Li
DBID AAYXX
CITATION
7X8
5PM
DOA
DOI 10.3389/fphar.2021.670900
DatabaseName CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE - Academic
DatabaseTitleList
CrossRef
Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
DocumentTitleAlternate Sun et al
EISSN 1663-9812
EndPage 670900
ExternalDocumentID oai_doaj_org_article_fa25d0fbb35c45908ccd4d2c5076e39d
10_3389_fphar_2021_670900
GroupedDBID 53G
5VS
9T4
AAFWJ
AAKDD
AAYXX
ACGFO
ACGFS
ACXDI
ADBBV
ADRAZ
AENEX
AFPKN
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
CITATION
DIK
EMOBN
GROUPED_DOAJ
GX1
HYE
IAO
IEA
IHR
IHW
KQ8
M48
M~E
O5R
O5S
OK1
P2P
PGMZT
RNS
RPM
7X8
5PM
ID FETCH-LOGICAL-c442t-ab8f8252487de6f1bdc1ecab85cf7bfb94ed85fe0d826a7fbb28cc9c48db8c3d3
IEDL.DBID RPM
ISSN 1663-9812
IngestDate Tue Oct 22 15:11:55 EDT 2024
Tue Sep 17 20:53:04 EDT 2024
Fri Oct 25 09:53:39 EDT 2024
Thu Sep 26 19:08:38 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Language English
License This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c442t-ab8f8252487de6f1bdc1ecab85cf7bfb94ed85fe0d826a7fbb28cc9c48db8c3d3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Carlos Mulet Forteza, University of the Balearic Islands, Spain
This article was submitted to Pharmacology of Anti-Cancer Drugs, a section of the journal Frontiers in Pharmacology
These authors share first authorship
Edited by:William Valentine Williams, BriaCell Therapeutics Corp., United States
Reviewed by:Fahmin Basher, University of Miami Hospital, United States
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8418110/
PMID 34489691
PQID 2570114039
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_fa25d0fbb35c45908ccd4d2c5076e39d
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8418110
proquest_miscellaneous_2570114039
crossref_primary_10_3389_fphar_2021_670900
PublicationCentury 2000
PublicationDate 2021-08-17
PublicationDateYYYYMMDD 2021-08-17
PublicationDate_xml – month: 08
  year: 2021
  text: 2021-08-17
  day: 17
PublicationDecade 2020
PublicationTitle Frontiers in pharmacology
PublicationYear 2021
Publisher Frontiers Media S.A
Publisher_xml – name: Frontiers Media S.A
References Yang (B91) 2020; 88
Mellman (B64) 2011; 480
Wang (B86) 2021; 12
Amaria (B3) 2018; 24
Maillet (B59) 2020; 132
Blank (B12) 2018; 24
Kieffer (B45) 2020; 10
Ishida (B40) 1992; 11
Liu (B55) 2020; 17
Gray (B34) 2020; 26
Sinkovics (B75) 2016; 33
Jing (B42) 2021
Wang (B87) 2020; 11
Blank (B11) 2004; 64
Brahmer (B13) 2018; 36
Mulet-Forteza (B67); 101
Tseng (B82) 2001; 193
Hirano (B39) 2005; 65
Wallis (B85) 2019; 5
Klein (B46) 2016; 16
Khalil (B44) 2016; 13
Wilson (B88) 2020; 69
Dominguez (B25) 2020; 10
Freeman (B29) 2000; 192
Merigó (B65) 2019; 21
Anderson (B4) 2016; 44
Lei (B50) 2021; 14
Alsaab (B2) 2017; 8
Kwok (B47) 2016; 12
Fukuoka (B30) 2020; 38
Ye (B92) 2020; 11
Ballot (B7) 2020; 12
Lei (B49) 2020; 8
Osipov (B70) 2019; 143
Dong (B27) 1999; 5
Guo (B36) 2020; 22
Dupont (B28) 2020; 9
Baş (B9) 2019; 18
Pinato (B73) 2019; 5
Griffiths (B35) 2020; 117
Gao (B32) 2019; 72
vom Steeg (B84) 2016; 12
Andrews (B5) 2019; 20
Bassez (B10) 2021; 27
Chang (B16) 2018; 2018
Li (B52) 2021; 13
Carter (B15) 2002; 32
Ding (B23) 2016
Hack (B37) 2020; 11
Chen (B17) 2006; 57
Martins (B60) 2019; 16
Sullivan (B78) 2020; 11
Zhao (B95) 2018; 97
Joseph (B43) 2020; 10
Lowe (B56) 2016; 4
Luoma (B57) 2020; 182
Chocarro de Erauso (B19) 2020; 11
Yan (B89) 2018; 9
Conforti (B20) 2018; 19
Mulet-Forteza (B68); 31
Zhao (B94) 2019; 12
Leydesdorff (B51) 2017; 11
Haile (B38) 2013; 191
Gainor (B31) 2016; 22
Svensson (B80) 2010; 44
Lisberg (B54) 2018; 13
Gohil (B33) 2021; 18
Jafarzadeh (B41) 2020; 157
Marur (B61) 2018; 45
Rozeman (B74) 2021; 27
Aria (B6) 2017; 11
Zuazo (B96) 2017; 5
Chen (B18) 2020; 8
Lurienne (B58) 2020; 15
Sun (B79) 2020; 8
Nosaki (B69) 2019; 135
Conforti (B21) 2019; 111
Teng (B81) 2018; 414
Brummelman (B14) 2018; 215
Spigel (B76) 2018; 13
Yi (B93) 2018; 17
Latchman (B48) 2001; 2
Dolladille (B24) 2020; 6
Pardoll (B71) 2012; 12
Su (B77) 2010; 85
McGrail (B63) 2021; 32
Das (B22) 2020; 25
Dong (B26) 2002; 8
McElroy (B62) 2020; 9
Motzer (B66) 2019; 380
Bang (B8) 2019; 15
Yang (B90) 2019; 14
van Eck (B83) 2010; 84
Ahn (B1) 2020; 2020
Lin (B53) 2020; 130
Penter (B72) 2019; 8
References_xml – volume: 380
  start-page: 1103
  year: 2019
  ident: B66
  article-title: Avelumab Plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
  publication-title: New Engl. J. Med.
  doi: 10.1056/NEJMoa1816047
  contributor:
    fullname: Motzer
– volume: 101
  start-page: 819
  ident: B67
  article-title: A Bibliometric Research in the Tourism, Leisure and Hospitality fields
  publication-title: J. Business Res.
  doi: 10.1016/j.jbusres.2018.12.002
  contributor:
    fullname: Mulet-Forteza
– volume: 24
  start-page: 1649
  year: 2018
  ident: B3
  article-title: Neoadjuvant Immune Checkpoint Blockade in High-Risk Resectable Melanoma
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0197-1
  contributor:
    fullname: Amaria
– volume: 11
  start-page: 3887
  year: 1992
  ident: B40
  article-title: Induced Expression of PD-1, a Novel Member of the Immunoglobulin Gene Superfamily, upon Programmed Cell Death
  publication-title: EMBO J.
  doi: 10.1002/j.1460-2075.1992.tb05481.x
  contributor:
    fullname: Ishida
– volume: 191
  start-page: 2829
  year: 2013
  ident: B38
  article-title: Soluble CD80 Restores T Cell Activation and Overcomes Tumor Cell Programmed Death Ligand 1-mediated Immune Suppression
  publication-title: J. Immunol.
  doi: 10.4049/jimmunol.1202777
  contributor:
    fullname: Haile
– volume: 15
  start-page: 943
  year: 2019
  ident: B8
  article-title: KEYNOTE-585: Phase III Study of Perioperative Chemotherapy with or without Pembrolizumab for Gastric Cancer
  publication-title: Future Oncol. (London, England)
  doi: 10.2217/fon-2018-0581
  contributor:
    fullname: Bang
– volume: 193
  start-page: 839
  year: 2001
  ident: B82
  article-title: B7-DC, a New Dendritic Cell Molecule with Potent Costimulatory Properties for T Cells
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.193.7.839
  contributor:
    fullname: Tseng
– volume: 8
  start-page: 35
  year: 2020
  ident: B79
  article-title: Resistance to PD-1/pd-L1 Blockade Cancer Immunotherapy: Mechanisms, Predictive Factors, and Future Perspectives
  publication-title: Biomarker Res.
  doi: 10.1186/s40364-020-00212-5
  contributor:
    fullname: Sun
– volume: 36
  start-page: 1714
  year: 2018
  ident: B13
  article-title: Management of Immune-Related Adverse Events in Patients Treated with Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
  publication-title: J. Clin. Oncol. : official J. Am. Soc. Clin. Oncol.
  doi: 10.1200/jco.2017.77.6385
  contributor:
    fullname: Brahmer
– volume: 192
  start-page: 1027
  year: 2000
  ident: B29
  article-title: Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.192.7.1027
  contributor:
    fullname: Freeman
– volume: 8
  start-page: 793
  year: 2002
  ident: B26
  article-title: Tumor-associated B7-H1 Promotes T-Cell Apoptosis: a Potential Mechanism of Immune Evasion
  publication-title: Nat. Med.
  doi: 10.1038/nm730
  contributor:
    fullname: Dong
– volume: 18
  start-page: 244
  year: 2021
  ident: B33
  article-title: Applying High-Dimensional Single-Cell Technologies to the Analysis of Cancer Immunotherapy
  publication-title: Nat. reviewsClinical Oncol.
  doi: 10.1038/s41571-020-00449-x
  contributor:
    fullname: Gohil
– volume: 64
  start-page: 1140
  year: 2004
  ident: B11
  article-title: PD-L1/B7H-1 Inhibits the Effector Phase of Tumor Rejection by T Cell Receptor (TCR) Transgenic CD8+ T Cells
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.can-03-3259
  contributor:
    fullname: Blank
– volume: 11
  start-page: 598877
  year: 2020
  ident: B37
  article-title: Augmenting Anticancer Immunity through Combined Targeting of Angiogenic and PD-1/pd-L1 Pathways: Challenges and Opportunities
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.598877
  contributor:
    fullname: Hack
– volume: 8
  start-page: e000492corr1
  year: 2020
  ident: B18
  article-title: Response and Outcomes after Anti-CTLA4 versus Anti-PD1 Combined with Stereotactic Body Radiation Therapy for Metastatic Non-small Cell Lung Cancer: Retrospective Analysis of Two Single-Institution Prospective Trials
  publication-title: J. Immunother. Cancer
  doi: 10.1136/jitc-2019-000492corr1
  contributor:
    fullname: Chen
– volume: 57
  start-page: 359
  year: 2006
  ident: B17
  article-title: CiteSpace II: Detecting and Visualizing Emerging Trends and Transient Patterns in Scientific Literature
  publication-title: J. Am. Soc. Inf. Sci. Technol.
  doi: 10.1002/asi.20317
  contributor:
    fullname: Chen
– volume: 14
  start-page: 553
  year: 2019
  ident: B90
  article-title: Pembrolizumab in Combination with Erlotinib or Gefitinib as First-Line Therapy for Advanced NSCLC with Sensitizing EGFR Mutation
  publication-title: J. Thorac. Oncol.
  doi: 10.1016/j.jtho.2018.11.028
  contributor:
    fullname: Yang
– start-page: djab035
  year: 2021
  ident: B42
  article-title: Association between Sex and Immune-Related Adverse Events during Immune Checkpoint Inhibitor Therapy
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djab035
  contributor:
    fullname: Jing
– volume: 8
  start-page: 561
  year: 2017
  ident: B2
  article-title: PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2017.00561
  contributor:
    fullname: Alsaab
– volume: 97
  start-page: e0276
  year: 2018
  ident: B95
  article-title: The Research Status of Immune Checkpoint Blockade by Anti-CTLA4 and Anti-pd1/pd-l1 Antibodies in Tumor Immunotherapy in China: A Bibliometrics Study
  publication-title: Medicine
  doi: 10.1097/md.0000000000010276
  contributor:
    fullname: Zhao
– volume: 20
  start-page: 1425
  year: 2019
  ident: B5
  article-title: Inhibitory Receptors and Ligands beyond PD-1, PD-L1 and CTLA-4: Breakthroughs or Backups
  publication-title: Nat. Immunol.
  doi: 10.1038/s41590-019-0512-0
  contributor:
    fullname: Andrews
– volume: 45
  start-page: 220
  year: 2018
  ident: B61
  article-title: FDA Analyses of Survival in Older Adults with Metastatic Non-small Cell Lung Cancer in Controlled Trials of PD-1/pd-L1 Blocking Antibodies
  publication-title: Semin. Oncol.
  doi: 10.1053/j.seminoncol.2018.08.007
  contributor:
    fullname: Marur
– volume: 2018
  start-page: 5068701
  year: 2018
  ident: B16
  article-title: αThe Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung Cancer
  publication-title: Dis. markers
  doi: 10.1155/2018/5068701
  contributor:
    fullname: Chang
– volume: 22
  start-page: 4585
  year: 2016
  ident: B31
  article-title: EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-small Cell Lung Cancer: A Retrospective Analysis
  publication-title: Clin. Cancer Res. : official J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.ccr-15-3101
  contributor:
    fullname: Gainor
– volume: 5
  start-page: 1365
  year: 1999
  ident: B27
  article-title: B7-H1, a Third Member of the B7 Family, Co-stimulates T-Cell Proliferation and Interleukin-10 Secretion
  publication-title: Nat. Med.
  doi: 10.1038/70932
  contributor:
    fullname: Dong
– volume: 9
  start-page: 1682383
  year: 2020
  ident: B28
  article-title: The Prognostic Impact of Immune-Related Adverse Events during Anti-PD1 Treatment in Melanoma and Non-small-cell Lung Cancer: a Real-Life Retrospective Study
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2019.1682383
  contributor:
    fullname: Dupont
– volume: 9
  start-page: 1050
  year: 2018
  ident: B89
  article-title: Prognostic Factors for Checkpoint Inhibitor Based Immunotherapy: An Update with New Evidences
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2018.01050
  contributor:
    fullname: Yan
– volume: 11
  start-page: 959
  year: 2017
  ident: B6
  article-title: Bibliometrix : An R-Tool for Comprehensive Science Mapping Analysis
  publication-title: J. Informetrics
  doi: 10.1016/j.joi.2017.08.007
  contributor:
    fullname: Aria
– volume: 215
  start-page: 2520
  year: 2018
  ident: B14
  article-title: High-dimensional Single Cell Analysis Identifies Stem-like Cytotoxic CD8 T Cells Infiltrating Human Tumors
  publication-title: J. Exp. Med.
  doi: 10.1084/jem.20180684
  contributor:
    fullname: Brummelman
– volume: 12
  start-page: 54
  year: 2019
  ident: B94
  article-title: Mismatch Repair Deficiency/microsatellite Instability-High as a Predictor for Anti-PD-1/pd-L1 Immunotherapy Efficacy
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-019-0738-1
  contributor:
    fullname: Zhao
– volume: 11
  start-page: 441
  year: 2020
  ident: B19
  article-title: Resistance to PD-L1/pd-1 Blockade Immunotherapy. A Tumor-Intrinsic or Tumor-Extrinsic Phenomenon?
  publication-title: Front. Pharmacol.
  doi: 10.3389/fphar.2020.00441
  contributor:
    fullname: Chocarro de Erauso
– volume: 44
  start-page: 989
  year: 2016
  ident: B4
  article-title: Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
  publication-title: Immunity
  doi: 10.1016/j.immuni.2016.05.001
  contributor:
    fullname: Anderson
– volume: 143
  start-page: 63
  year: 2019
  ident: B70
  article-title: From Immune Checkpoints to Vaccines: The Past, Present and Future of Cancer Immunotherapy
  publication-title: Adv. Cancer Res.
  doi: 10.1016/bs.acr.2019.03.002
  contributor:
    fullname: Osipov
– volume: 6
  start-page: 865
  year: 2020
  ident: B24
  article-title: Immune Checkpoint Inhibitor Rechallenge after Immune-Related Adverse Events in Patients with Cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2020.0726
  contributor:
    fullname: Dolladille
– volume: 17
  start-page: 13
  year: 2020
  ident: B55
  article-title: Targeting Innate Sensing in the Tumor Microenvironment to Improve Immunotherapy
  publication-title: Cell Mol. Immunol.
  doi: 10.1038/s41423-019-0341-y
  contributor:
    fullname: Liu
– volume: 13
  start-page: 1383
  year: 2021
  ident: B52
  article-title: The Top 100 Most Frequently Cited Publications Concerning Anti-PD-1/pd-L1 Therapy for Lung Cancer: A Bibliometric Analysis
  publication-title: Cancer Manag. Res.
  doi: 10.2147/cmar.S270099
  contributor:
    fullname: Li
– volume: 10
  start-page: 143
  year: 2020
  ident: B43
  article-title: Immune-related Adverse Events: a Retrospective Look into the Future of Oncology in the Intensive Care Unit
  publication-title: Ann. Intensive Care
  doi: 10.1186/s13613-020-00761-w
  contributor:
    fullname: Joseph
– volume: 132
  start-page: 61
  year: 2020
  ident: B59
  article-title: Association between Immune-Related Adverse Events and Long-Term Survival Outcomes in Patients Treated with Immune Checkpoint Inhibitors
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2020.03.017
  contributor:
    fullname: Maillet
– volume: 72
  start-page: 374
  year: 2019
  ident: B32
  article-title: Bibliometric Analysis of Global Research on PD-1 and PD-L1 in the Field of Cancer
  publication-title: Int. immunopharmacology
  doi: 10.1016/j.intimp.2019.03.045
  contributor:
    fullname: Gao
– volume: 12
  start-page: e1005374
  year: 2016
  ident: B84
  article-title: SeXX Matters in Infectious Disease Pathogenesis
  publication-title: PLoS Pathog.
  doi: 10.1371/journal.ppat.1005374
  contributor:
    fullname: vom Steeg
– volume: 22
  start-page: e18228
  year: 2020
  ident: B36
  article-title: Artificial Intelligence in Health Care: Bibliometric Analysis
  publication-title: J. Med. Internet Res.
  doi: 10.2196/18228
  contributor:
    fullname: Guo
– volume: 32
  start-page: 661
  year: 2021
  ident: B63
  article-title: High Tumor Mutation burden Fails to Predict Immune Checkpoint Blockade Response across All Cancer Types
  publication-title: Ann. Oncol. : official J. Eur. Soc. Med. Oncol.
  doi: 10.1016/j.annonc.2021.02.006
  contributor:
    fullname: McGrail
– volume: 11
  start-page: 1779
  year: 2020
  ident: B92
  article-title: Sex-associated Molecular Differences for Cancer Immunotherapy
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-15679-x
  contributor:
    fullname: Ye
– volume: 16
  start-page: 563
  year: 2019
  ident: B60
  article-title: Adverse Effects of Immune-Checkpoint Inhibitors: Epidemiology, Management and Surveillance
  publication-title: Nat. Rev. Clin. Oncol.
  doi: 10.1038/s41571-019-0218-0
  contributor:
    fullname: Martins
– volume: 2
  start-page: 261
  year: 2001
  ident: B48
  article-title: PD-L2 Is a Second Ligand for PD-1 and Inhibits T Cell Activation
  publication-title: Nat. Immunol.
  doi: 10.1038/85330
  contributor:
    fullname: Latchman
– volume: 13
  start-page: 1138
  year: 2018
  ident: B54
  article-title: A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients with Advanced NSCLC
  publication-title: J. Thorac. Oncol. : official Publ. Int. Assoc. Study Lung Cancer
  doi: 10.1016/j.jtho.2018.03.035
  contributor:
    fullname: Lisberg
– volume: 44
  start-page: 23
  year: 2010
  ident: B80
  article-title: SSCI and its Impact Factors: a “Prisoner's Dilemma”?
  publication-title: Eur. J. Marketing
  doi: 10.1108/03090561011008583
  contributor:
    fullname: Svensson
– volume: 5
  start-page: 1774
  year: 2019
  ident: B73
  article-title: Association of Prior Antibiotic Treatment with Survival and Response to Immune Checkpoint Inhibitor Therapy in Patients with Cancer
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2019.2785
  contributor:
    fullname: Pinato
– volume: 11
  start-page: 979
  year: 2020
  ident: B78
  article-title: Quantifying the Efficacy of Checkpoint Inhibitors on CD8 Cytotoxic T Cells for Immunotherapeutic Applications via Single-Cell Interaction
  publication-title: Cel Death Dis.
  doi: 10.1038/s41419-020-03173-7
  contributor:
    fullname: Sullivan
– volume: 21
  start-page: 881
  year: 2019
  ident: B65
  article-title: Twenty Years of Tourism Geographies: a Bibliometric Overview
  publication-title: Tourism Geographies
  doi: 10.1080/14616688.2019.1666913
  contributor:
    fullname: Merigó
– volume: 135
  start-page: 188
  year: 2019
  ident: B69
  article-title: Safety and Efficacy of Pembrolizumab Monotherapy in Elderly Patients with PD-L1-Positive Advanced Non-small-cell Lung Cancer: Pooled Analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 Studies
  publication-title: Lung cancer.
  doi: 10.1016/j.lungcan.2019.07.004
  contributor:
    fullname: Nosaki
– volume: 17
  start-page: 129
  year: 2018
  ident: B93
  article-title: Biomarkers for Predicting Efficacy of PD-1/pd-L1 Inhibitors
  publication-title: Mol. Cancer
  doi: 10.1186/s12943-018-0864-3
  contributor:
    fullname: Yi
– volume: 8
  start-page: 672
  year: 2020
  ident: B49
  article-title: Resistance Mechanisms of Anti-pd1/pdl1 Therapy in Solid Tumors
  publication-title: Front. Cel. Dev. Biol.
  doi: 10.3389/fcell.2020.00672
  contributor:
    fullname: Lei
– volume: 11
  start-page: 117
  year: 2017
  ident: B51
  article-title: Full and Fractional Counting in Bibliometric Networks
  publication-title: J. Informetrics
  doi: 10.1016/j.joi.2016.11.007
  contributor:
    fullname: Leydesdorff
– volume: 5
  start-page: 529
  year: 2019
  ident: B85
  article-title: Association of Patient Sex with Efficacy of Immune Checkpoint Inhibitors and Overall Survival in Advanced Cancers: A Systematic Review and Meta-Analysis
  publication-title: JAMA Oncol.
  doi: 10.1001/jamaoncol.2018.5904
  contributor:
    fullname: Wallis
– volume: 13
  start-page: 273
  year: 2016
  ident: B44
  article-title: The Future of Cancer Treatment: Immunomodulation, CARs and Combination Immunotherapy
  publication-title: Nat. reviewsClinical Oncol.
  doi: 10.1038/nrclinonc.2016.25
  contributor:
    fullname: Khalil
– volume: 27
  start-page: 820
  year: 2021
  ident: B10
  article-title: A Single-Cell Map of Intratumoral Changes during Anti-PD1 Treatment of Patients with Breast Cancer
  publication-title: Nat. Med.
  doi: 10.1038/s41591-021-01323-8
  contributor:
    fullname: Bassez
– volume: 157
  start-page: 103161
  year: 2020
  ident: B41
  article-title: Biomarkers for Predicting the Outcome of Various Cancer Immunotherapies
  publication-title: Crit. Rev. oncology/hematology
  doi: 10.1016/j.critrevonc.2020.103161
  contributor:
    fullname: Jafarzadeh
– volume: 18
  start-page: 1176935119852620
  year: 2019
  ident: B9
  article-title: A Holistic Evaluation of Articles on PD-1 and PD-L1 Published between 1975 and 2017: A Bibliometric Analysis
  publication-title: Cancer Inform.
  doi: 10.1177/1176935119852620
  contributor:
    fullname: Baş
– volume: 117
  start-page: 16072
  year: 2020
  ident: B35
  article-title: Circulating Immune Cell Phenotype Dynamics Reflect the Strength of Tumor-Immune Cell Interactions in Patients during Immunotherapy
  publication-title: Proc. Natl. Acad. Sci. United States America
  doi: 10.1073/pnas.1918937117
  contributor:
    fullname: Griffiths
– volume: 13
  start-page: 682
  year: 2018
  ident: B76
  article-title: Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-small Cell Lung Cancer (CheckMate 370)
  publication-title: J. Thorac. Oncol. : official Publ. Int. Assoc. Study Lung Cancer
  doi: 10.1016/j.jtho.2018.02.022
  contributor:
    fullname: Spigel
– volume: 26
  start-page: 6003
  year: 2020
  ident: B34
  article-title: PD1 Blockade Enhances ICAM1-Directed CAR T Therapeutic Efficacy in Advanced Thyroid Cancer
  publication-title: Clin. Cancer Res. : official J. Am. Assoc. Cancer Res.
  doi: 10.1158/1078-0432.ccr-20-1523
  contributor:
    fullname: Gray
– volume: 11
  start-page: 1187
  year: 2020
  ident: B87
  article-title: Bibliometrics Analysis of Butyrophilins as Immune Regulators [1992-2019] and Implications for Cancer Prognosis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2020.01187
  contributor:
    fullname: Wang
– volume: 5
  start-page: 385
  year: 2017
  ident: B96
  article-title: Molecular Mechanisms of Programmed Cell Death-1 Dependent T Cell Suppression: Relevance for Immunotherapy
  publication-title: Ann. translational Med.
  doi: 10.21037/atm.2017.06.11
  contributor:
    fullname: Zuazo
– volume: 19
  start-page: 737
  year: 2018
  ident: B20
  article-title: Cancer Immunotherapy Efficacy and Patients' Sex: a Systematic Review and Meta-Analysis
  publication-title: Lancet Oncol.
  doi: 10.1016/s1470-2045(18)30261-4
  contributor:
    fullname: Conforti
– volume: 33
  start-page: 327
  year: 2016
  ident: B75
  article-title: Enhancing the Foundations for Theorising through Bibliometric Mapping
  publication-title: Int. Marketing Rev.
  doi: 10.1108/imr-10-2014-0341
  contributor:
    fullname: Sinkovics
– volume: 38
  start-page: 2053
  year: 2020
  ident: B30
  article-title: Regorafenib Plus Nivolumab in Patients with Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603)
  publication-title: J. Clin. Oncol. : official J. Am. Soc. Clin. Oncol.
  doi: 10.1200/jco.19.03296
  contributor:
    fullname: Fukuoka
– volume: 9
  start-page: 439
  year: 2020
  ident: B62
  article-title: A Bibliometric Review of Publications on Oxidative Stress and Chemobrain: 1990-2019
  publication-title: Antioxidants (Basel).
  doi: 10.3390/antiox9050439
  contributor:
    fullname: McElroy
– volume: 85
  start-page: 65
  year: 2010
  ident: B77
  article-title: Mapping Knowledge Structure by Keyword Co-occurrence: a First Look at Journal Papers in Technology Foresight
  publication-title: Scientometrics
  doi: 10.1007/s11192-010-0259-8
  contributor:
    fullname: Su
– volume: 69
  start-page: 343
  year: 2020
  ident: B88
  article-title: The Effect of Antibiotics on Clinical Outcomes in Immune-Checkpoint Blockade: a Systematic Review and Meta-Analysis of Observational Studies
  publication-title: Cancer Immunol. Immunother.
  doi: 10.1007/s00262-019-02453-2
  contributor:
    fullname: Wilson
– volume: 84
  start-page: 523
  year: 2010
  ident: B83
  article-title: Software Survey: VOSviewer, a Computer Program for Bibliometric Mapping
  publication-title: Scientometrics
  doi: 10.1007/s11192-009-0146-3
  contributor:
    fullname: van Eck
– volume: 88
  start-page: 106876
  year: 2020
  ident: B91
  article-title: Antibiotic Administration Shortly before or after Immunotherapy Initiation Is Correlated with Poor Prognosis in Solid Cancer Patients: An Up-To-Date Systematic Review and Meta-Analysis
  publication-title: Int. immunopharmacology
  doi: 10.1016/j.intimp.2020.106876
  contributor:
    fullname: Yang
– volume: 27
  start-page: 256
  year: 2021
  ident: B74
  article-title: Survival and Biomarker Analyses from the OpACIN-Neo and OpACIN Neoadjuvant Immunotherapy Trials in Stage III Melanoma
  publication-title: Nat. Med.
  doi: 10.1038/s41591-020-01211-7
  contributor:
    fullname: Rozeman
– volume: 12
  start-page: 2418
  year: 2020
  ident: B7
  article-title: Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/pd-L1 Efficacy
  publication-title: Cancers
  doi: 10.3390/cancers12092418
  contributor:
    fullname: Ballot
– volume: 31
  start-page: 4574
  ident: B68
  article-title: Bibliometric Structure of IJCHM in its 30 Years
  publication-title: Int. J. Contemp. Hospitality Manage.
  doi: 10.1108/ijchm-10-2018-0828
  contributor:
    fullname: Mulet-Forteza
– volume: 2020
  start-page: 4708394
  year: 2020
  ident: B1
  article-title: Global Trends in Immunotherapy Research on Breast Cancer over the Past 10 Years
  publication-title: J. Oncol.
  doi: 10.1155/2020/4708394
  contributor:
    fullname: Ahn
– volume: 24
  start-page: 1655
  year: 2018
  ident: B12
  article-title: Neoadjuvant versus Adjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma
  publication-title: Nat. Med.
  doi: 10.1038/s41591-018-0198-0
  contributor:
    fullname: Blank
– volume: 25
  start-page: 669
  year: 2020
  ident: B22
  article-title: Immune-Related Adverse Events and Immune Checkpoint Inhibitor Efficacy in Patients with Gastrointestinal Cancer with Food and Drug Administration-Approved Indications for Immunotherapy
  publication-title: The oncologist
  doi: 10.1634/theoncologist.2019-0637
  contributor:
    fullname: Das
– volume: 12
  start-page: 2777
  year: 2016
  ident: B47
  article-title: Pembrolizumab (Keytruda)
  publication-title: Hum. Vaccin. Immunother.
  doi: 10.1080/21645515.2016.1199310
  contributor:
    fullname: Kwok
– volume: 480
  start-page: 480
  year: 2011
  ident: B64
  article-title: Cancer Immunotherapy Comes of Age
  publication-title: Nature
  doi: 10.1038/nature10673
  contributor:
    fullname: Mellman
– volume: 12
  start-page: 669539
  year: 2021
  ident: B86
  article-title: Global Trends in Research of Macrophages Associated with Acute Lung Injury over Past 10 years: A Bibliometric Analysis
  publication-title: Front. Immunol.
  doi: 10.3389/fimmu.2021.669539
  contributor:
    fullname: Wang
– volume: 15
  start-page: 1147
  year: 2020
  ident: B58
  article-title: NSCLC Immunotherapy Efficacy and Antibiotic Use: A Systematic Review and Meta-Analysis
  publication-title: J. Thorac. Oncol. : official Publ. Int. Assoc. Study Lung Cancer
  doi: 10.1016/j.jtho.2020.03.002
  contributor:
    fullname: Lurienne
– volume: 65
  start-page: 1089
  year: 2005
  ident: B39
  article-title: Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.1089.65.3
  contributor:
    fullname: Hirano
– volume: 16
  start-page: 626
  year: 2016
  ident: B46
  article-title: Sex Differences in Immune Responses
  publication-title: Nat. Rev. Immunol.
  doi: 10.1038/nri.2016.90
  contributor:
    fullname: Klein
– volume: 130
  start-page: 2560
  year: 2020
  ident: B53
  article-title: Pembrolizumab Plus Allogeneic NK Cells in Advanced Non-small Cell Lung Cancer Patients
  publication-title: J. Clin. Invest.
  doi: 10.1172/jci132712
  contributor:
    fullname: Lin
– volume: 12
  start-page: 252
  year: 2012
  ident: B71
  article-title: The Blockade of Immune Checkpoints in Cancer Immunotherapy
  publication-title: Nat. Rev. Cancer
  doi: 10.1038/nrc3239
  contributor:
    fullname: Pardoll
– volume: 8
  start-page: e1586409
  year: 2019
  ident: B72
  article-title: Localization-associated Immune Phenotypes of Clonally Expanded Tumor-Infiltrating T Cells and Distribution of Their Target Antigens in Rectal Cancer
  publication-title: Oncoimmunology
  doi: 10.1080/2162402x.2019.1586409
  contributor:
    fullname: Penter
– volume: 10
  start-page: 1330
  year: 2020
  ident: B45
  article-title: Single-Cell Analysis Reveals Fibroblast Clusters Linked to Immunotherapy Resistance in Cancer
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.Cd-19-1384
  contributor:
    fullname: Kieffer
– volume: 414
  start-page: 166
  year: 2018
  ident: B81
  article-title: Progress and Challenges of Predictive Biomarkers of Anti PD-1/pd-L1 Immunotherapy: A Systematic Review
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2017.11.014
  contributor:
    fullname: Teng
– volume: 32
  start-page: 634
  year: 2002
  ident: B15
  article-title: PD-1:PD-L Inhibitory Pathway Affects Both CD4(+) and CD8(+) T Cells and Is Overcome by IL-2
  publication-title: Eur. J. Immunol.
  doi: 10.1002/1521-4141(200203)32:3<634::aid-immu634>3.0.co;2-9
  contributor:
    fullname: Carter
– volume: 111
  start-page: 772
  year: 2019
  ident: B21
  article-title: Sex-Based Heterogeneity in Response to Lung Cancer Immunotherapy: A Systematic Review and Meta-Analysis
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djz094
  contributor:
    fullname: Conforti
– volume: 10
  start-page: 232
  year: 2020
  ident: B25
  article-title: Single-Cell RNA Sequencing Reveals Stromal Evolution into LRRC15 Myofibroblasts as a Determinant of Patient Response to Cancer Immunotherapy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.Cd-19-0644
  contributor:
    fullname: Dominguez
– volume: 4
  start-page: 89
  year: 2016
  ident: B56
  article-title: Genetic Risk Analysis of a Patient with Fulminant Autoimmune Type 1 Diabetes Mellitus Secondary to Combination Ipilimumab and Nivolumab Immunotherapy
  publication-title: J. Immunother. Cancer
  doi: 10.1186/s40425-016-0196-z
  contributor:
    fullname: Lowe
– volume: 14
  start-page: 91
  year: 2021
  ident: B50
  article-title: Applications of Single-Cell Sequencing in Cancer Research: Progress and Perspectives
  publication-title: J. Hematol. Oncol.
  doi: 10.1186/s13045-021-01105-2
  contributor:
    fullname: Lei
– volume-title: Measuring Scholarly Impact
  year: 2016
  ident: B23
  contributor:
    fullname: Ding
– volume: 182
  start-page: 655
  year: 2020
  ident: B57
  article-title: Molecular Pathways of Colon Inflammation Induced by Cancer Immunotherapy
  publication-title: Cell
  doi: 10.1016/j.cell.2020.06.001
  contributor:
    fullname: Luoma
SSID ssj0000399364
Score 2.3503704
Snippet The programmed death receptor 1 (PD1) and its ligand programmed death receptor ligand 1 (PDL1) are the most widely used immune checkpoints in cancer...
SourceID doaj
pubmedcentral
proquest
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
StartPage 670900
SubjectTerms bibliometrics
immune checkpoint blockade
meta-analysis
PD1/PDL1
Pharmacology
randomized clinical trials
SummonAdditionalLinks – databaseName: Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV07b9swECaKTF2KtmlR9xEwQJGhiGpRoh7MZjsJkqItPCRANoJPWEhAGYkyaOtPz51oN9bUpaNIgaL4ncjvxLuPhHzVDjh9XbikYFolvCp5ohXXCWdOlIp5qMds5F-_y4tr_uOmuNk56gtjwqI8cBy4qVdZYVOvdV4Yjgd0G2O5zQzwmNLlwg6zbyp2nKlhDsZ1t-RxGxO8MDH165VC_c-MfUfJMsxo21mIBr3-Eckch0jurDnnr8mrDVmks9jJN-SFC2_J0TKqTffH9Oo5eerhmB7R5bMOdb9P_sR4V9oECiyPbmPs6GXoWnqJeSGOLlbO3K7bJnR0DsvarbKO6p7OQtcky1M2XZ7-ZMOVbjHcENtaoJ3cxwY26Vv9CZ3ReaPvMJcfJf8phif278j1-dnV4iLZHLiQGM6zLlG69uAxZuDEWFd6pq1hzkBpYXylvRbc2brwLrXglKgKQMkADmF4bXVtcpu_J3uhDe4DoVboPHVaMIUeZ8a1qYHZ8RLc8boGzjYh37ajL9dRV0OCP4JQyQEqiVDJCNWEzBGfvzeiJPZQAIYiN4Yi_2UoE3K4RVfCJ4T7Iiq49vFB4kF-DHULxYRUI9hHTxzXhGY1iHHXHDgSSz_-jy5-Ii_xrfGXNas-k73u_tF9Ac7T6YPBvJ8AGb4EbQ
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1La9wwEBYhvfRS-qTbFyqUHEqcWLZsy4VSdjcNSWnLHrKQm9CzaxLk7a4D9a0_vTO2t6khhx4tG9nWSJ7vs2a-IeSddoDpReaijGkV8SLnkVZcR5y5MlfMw3nMRv72PT9b8i-X2eUe2ZW3GgZweye1w3pSy8310a-f7SdY8B-RcYK_PfbrlUJpz4QdoRpZDAz-XsKBqGMk34D2uw8zOuNOUIqBn41K8G39PufdvYw8VSfoP0Kh4xjKf5zS6UPyYECTdNqb_xHZc-ExOVj0ctTtIb24za7aHtIDurgVqm6fkN99QCytAgUYSHdBePQ8NDU9x8QRR-crZ67WdRUaOgO_d6Wso7ql09BU0eKEHS9OvrLuSNcYj4h9zXEibfoOhvyu9gOd0lmlrzHZH2sCUIxfbJ-S5enni_lZNFRkiAznSRMpLTxQygRYjnW5Z9oa5gy0ZsYX2uuSOysy72ILrEUVXutEGFMaLqwWJrXpM7If6uCeE2pLncZOl0whJU24NgKgH8-BrwsBoG5C3u9GX6574Q0JhAVNJTtTSTSV7E01ITO0z98LUTO7a6g3P-SwBKVXSWZjeKY0MxxLvRtjuU0MIOLcpaWdkLc760pYY7hxooKrb7YSK_0xFDYsJ6QYmX10x_GZUK06tW7BAUSx-MV_9P6S3MeXwl_WrHhF9pvNjXsNmKfRb7qZ_AdTPQLK
  priority: 102
  providerName: Scholars Portal
Title Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
URI https://search.proquest.com/docview/2570114039
https://pubmed.ncbi.nlm.nih.gov/PMC8418110
https://doaj.org/article/fa25d0fbb35c45908ccd4d2c5076e39d
Volume 12
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb5wwELaSnHqp-lS3j8iVqhyqsGAwYHrb3TRKqm7FIZFyQ_hBFyUxqw05cMtPz4yBJlx7QcLmYZiBmc-e-YaQb9KATy9i48VMlh5PE-7JkkuPM5MlJaugH7OR13-Ss0v-6yq-2iPxmAvjgvaVrOf25nZu642LrdzeKn-ME_Pz9UpwsEss8PfJPijoM4jufr9ochPer2ACAMv8arspkfozZHNkKwuw-lsEsCRLMjYxR461f-JqTgMln1me01fk5eAy0kU_tNdkz9g35CjvOae7Y3rxlEJ1d0yPaP7ERt29JQ991CutLQVfj46RdvTctg09x-wQQ1cbo663TW1bugTjdl1qQ2VHF7atvfyE-fnJb-b2ZINBh3itFWrLrr_AkMTV_aALuqzlDWb0I_E_xSDF7h25PP15sTrzhrILnuI8bL1SigpwYwhQRpukYlIrZhS0xqpKZSUzbrSIKxNogCZlWkkZCqUyxYWWQkU6ek8ObGPNB0J1JqPAyIyViDtDLhXILeQJgHIhwHObke_j2y-2PbtGAagEpVY4qRUotaKX2owsUT7_DkRibNfQ7P4Wg3oUVRnGOoAxRbHiWM9dKc11qMDtTUyU6Rn5Okq3gA8JV0dKa5r7uwLL-TFkL8xmJJ2IfXLHaQ9oqKPkHjTy43-f-Ym8wEfF2WqWfiYH7e7efAF3p5WHbpoAtmsuDp2qPwIS_AXV
link.rule.ids 230,315,730,783,787,867,888,2109,24330,27936,27937,53804,53806
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Jb9NAFB6VcoALO2pYBwn1gOpl7PHGLUmpEkgqH1LUm-VZTKy0dpQ6B3Pip_OeF1pzg2M8sWNnvvF7n_297xHyUWjI6UNPGx4TqcEDnxsi5cLgTEd-yjIYx2rk5bk_u-BfL73LA-L1tTCNaF-K3Cyurs0iXzfayu21tHqdmBUvpyGHuMRs6x65D-vV5ndIenMDxqDr8_YdJlCwyMq26xTNPx1mol-Zjf3fXCAmkR-xQUBqfPsHyeZQKnkn9pw9Jt_7s24lJxtzXwlT_vzL0PGfL-sJedRlo3TcDj8lB7p4Ro7j1s66PqGr2-qsmxN6TONbo-v6OfnVCmppXlBII2kv4qPzoirpHAtPNJ2utdxsy7yo6ATi5iZVmoqajosqN-JTZsWnC9Z8EiXqGfFYUwTirj1AVx9Wf6ZjOsnFFZoFYE8BivrH-gW5OPuyms6MrqODITl3KiMVYQaU1AGWpLSfMaEk0xK2ejILRCYirlXoZdpWwHrSIBPCCaWMJA-VCKWr3JfksCgLfUSoioRraxGxFCmtw4WE_87hPvD9MISkcEQ-9dOabFvjjgQID8IhaeCQIBySFg4jMsGJ__NF9NxuNpS7H0k3RUmWOp6y4ZxcT3JsFS-l4sqRkFH72o3UiHzoYZPAGsUXL2mhy_1Ngp0CGRojRiMSDPA0-MXhCKCkcfvuUPHqv_d8Tx7MVstFspiff3tNHuJl40NxFrwhh9Vur99CVlWJd80a-g2ujCXz
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3JbtRAEG1BkBAXdsSwNhLKAcVL2-2N2yyMMpBEPiRSxMVyL2asSWxr4jmYE59OlRcy5pij97b7taue_foVIZ-Fhpw-9LThMZEaPPC5IVIuDM505Kcsg-04G_n0zD--4N8vvcu9Ul-taF-K3Cyurs0iX7fayupaWoNOzIpP5yGHuMRsq1KZdZ88gDFr-3tEvX0JY-D1efcfE2hYZGXVOkUDUIeZ6FlmYw04F8hJ5EdsFJRa7_5RwjmWS-7Fn-UT8nNoeSc72Zi7Wpjy93-mjne6tafkcZ-V0mm3yzNyTxfPyWHc2Vo3R_T8dpbWzRE9pPGt4XXzgvzphLU0Lyikk3QQ89FVUZd0hRNQNJ2vtdxUZV7UdAbxc5MqTUVDp0WdG_GCWfHihLVLokRdI55rjoDcdifo54k1X-mUznJxhaYBWFuAog6yeUkult_O58dGX9nBkJw7tZGKMANq6gBbUtrPmFCSaQlrPZkFIhMR1yr0Mm0rYD9pkAnhhFJGkodKhNJV7ityUJSFfk2oioRraxGxFKmtw4WE5-dwH3h_GEJyOCFfhq5Nqs7AIwHig5BIWkgkCImkg8SEzLDz_-2I3tvtinL7K-m7KclSx1M2tMn1JMeS8VIqrhwJmbWv3UhNyKcBOgmMVfwBkxa63N0kWDGQoUFiNCHBCFOjK463AFJa1-8eGW_ufORH8jBeLJOT1dmPt-QR3jV-G2fBO3JQb3f6PSRXtfjQDqO_wAEocw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Trends+in+the+Research+Into+Immune+Checkpoint+Blockade+by+Anti-PD1%2FPDL1+Antibodies+in+Cancer+Immunotherapy%3A+A+Bibliometric+Study&rft.jtitle=Frontiers+in+pharmacology&rft.au=Sun%2C+Yiting&rft.au=Jiang%2C+Liqing&rft.au=Wen%2C+Ti&rft.au=Guo%2C+Xiaoyu&rft.date=2021-08-17&rft.issn=1663-9812&rft.eissn=1663-9812&rft.volume=12&rft.spage=670900&rft.epage=670900&rft_id=info:doi/10.3389%2Ffphar.2021.670900&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1663-9812&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1663-9812&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1663-9812&client=summon